The BioE3 Policy 2024 targets a US$300 billion bioeconomy by 2030. Examine the role of the National Biofoundry Network, the genome-edited rice release of May 2025, and the unfinished GM-crop regulatory architecture.

Introduction:

The BioE3 Policy was approved by the Union Cabinet on 24 August 2024, targeting a US$300 billion bioeconomy by 2030 from a base of US$195.3 billion in 2025 (~4.8% of GDP); the DBT India Bioeconomy Report (2025) records 11,855 biotech startups. BioE3 reframes biotechnology around economy, employment, and environment.

Six BioE3 sectors:

The policy targets bio-based chemicals, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilisation, and marine and space biotechnology — anchored by enabling biofoundries.

National Biofoundry Network:

21 biofoundry facilities were launched on 1 September 2025, providing automated DNA synthesis, strain engineering, and scale-up for startups and academia — closing the gap between research and translation that has historically constrained Indian biotech.

Genome-edited rice breakthrough:

Kamala (DRR Dhan 100) by ICAR-IIRR Hyderabad and Pusa DST Rice 1 by ICAR-IARI were released on 4 May 2025 under the SDN-1 CRISPR exemption — recording ~19% higher yield, 20% lower methane emissions, and 20 days earlier maturity. This signals SDN-1's mainstream arrival in Indian agriculture.

Regulatory unfinished business:

The Supreme Court split verdict on GM mustard DMH-11 (July 2024) directed the Centre to frame a National GM Crop Policy. GEAC continues under Rules 1989 of EPA 1986 — without an independent statutory regulator.

Way forward / Conclusion:

Operationalise a National GM Crop Policy, replace GEAC with a Biotechnology Regulatory Authority of India, open biofoundry access to all DBT-registered startups, and align SDN-1 exemptions with EU and US norms by 2027.